Review Article

Autophagy Paradox of Cancer: Role, Regulation, and Duality

Amit Kumar Verma,1 Prahalad Singh Bharti,2 Sahar Rafat,1 Deepti Bhatt,1 Yamini Goyal,1 Kamlesh Kumar Pandey,3 Sanjeev Ranjan,4 Saleh A. Almatroodi,5 Mohammed A. Alsahli,5 Arshad Husain Rahmani1,5, Ahmad Almatroudi1,5, and Kapil Dev1

1Department of Biotechnology, Jamia Millia Islamia, New Delhi, India
2Department of Biophysics, All India Institutes of Medical Sciences, New Delhi, India
3Department of Anatomy, All India Institutes of Medical Sciences, New Delhi, India
4Institute of Biomedicine, Cell and Tissue Imaging Unit, Finland
5Department of Medical Laboratories, College of Applied Medical Science, Qassim University, Buraidah, Saudi Arabia

Correspondence should be addressed to Kapil Dev; kdev@jmi.ac.in

Received 9 September 2020; Revised 14 January 2021; Accepted 29 January 2021; Published 11 February 2021

Academic Editor: Maria C. Albertini

Copyright © 2021 Amit Kumar Verma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Autophagy, a catabolic process, degrades damaged and defective cellular materials through lysosomes, thus working as a recycling mechanism of the cell. It is an evolutionarily conserved and highly regulated process that plays an important role in maintaining cellular homeostasis. Autophagy is constitutively active at the basal level; however, it gets enhanced to meet cellular needs in various stress conditions. The process involves various autophagy-related genes that ultimately lead to the degradation of targeted cytosolic substrates. Many factors modulate both upstream and downstream autophagy pathways like nutritional status, energy level, growth factors, hypoxic conditions, and localization of p53. Any problem in executing autophagy can lead to various pathological conditions including neurodegeneration, aging, and cancer. In cancer, autophagy plays a contradictory role; it inhibits the formation of tumors, whereas, during advanced stages, autophagy promotes tumor progression. Besides, autophagy protects the tumor from various therapies by providing recycled nutrition and energy to the tumor cells. Autophagy is stimulated by tumor suppressor proteins, whereas it gets inhibited by oncogenes. Due to its dynamic and dual role in the pathogenesis of cancer, autophagy provides promising opportunities in developing novel and effective cancer therapies along with managing chemoresistant cancers. In this article, we summarize different strategies that can modulate autophagy in cancer to overcome the major obstacle, i.e., resistance developed in cancer to anticancer therapies.

1. Introduction

The term “autophagy” comes from “auto” and “phagy”, which means, respectively, “self” and “eating” in Greek. It is an evolutionary conserved catabolic process, critically required for the maintenance of cellular homeostasis, metabolism, and growth regulation. It is a self-degrading system in which autophagic substrates like damaged organelles, misfolded/aggregated proteins, and enzyme complexes are degraded. Autophagy acts as a quality control mechanism in cells. Physiologically, it is a strategy of survival under stress conditions by the renewal of the by-products such as amino acids, fatty acids, nucleotides, and carbohydrates. It is constitutively active at the basal level in healthy cells, under the tight regulation of the mammalian target of rapamycin (mTOR) and adenosine monophosphate-activated protein kinase (AMPK). The level gets significantly increased under stress conditions [1–3]. Apart from the degrading nature, it additionally takes part in biosynthetic and secretory processes [4]. It also has roles in development, differentiation [5, 6] organellar remodelling, quality control of organelles and proteins, genotoxic stress prevention, suppression of tumor, elimination of pathogen, immunity and inflammation regulation, maternal DNA inheritance, and programmed cell death [7, 8]. Malfunctioned autophagy is related to a variety of human maladies such as neurodegeneration, aging, and
cancer [9]. Autophagy is also known as type II cell death mechanism. It has been found in some circumstances that autophagy can lead to cell death; for instance, autophagy shows association in degenerating neurons of Parkinson’s and Alzheimer’s patients, in MCF-7 cancer cell lines treated with 4-hydroxyxytamoxifen (selective estrogen receptor modulator), in the regression of corpus luteum [10], deterioration of Mullerian duct structure during male genital development [11], and involution of mammary and prostate glands [12–15]. But recent in vivo and in vitro studies suggested that autophagy acts as a major survival mechanism in response to various stresses like nutrient depletion, hypoxia, damaged organelles, accumulation of anomalous proteins, activated oncogenes, and deactivated tumor suppressor genes [16]. This review discusses the role, regulation of autophagy with a focus on cancer, and how autophagy is responsible in causing resistance to various cancer therapies. We summarized different strategies like pharmacological, RNA-based therapies and combinational drug therapies; conventional drugs with new formulations (nanoformulation) are inhibiting the autophagy and overcoming the autophagy-mediated tumor resistance against therapies. Besides, we also discussed about activators of autophagy as anticancer agents. Different drugs, natural products, or extracts along with siRNA combination enhance autophagy-mediated tumor cell death both in vivo and in vitro studies.

2. Autophagy Pathway

Autophagy, also referred to as macroautophagy, is an effective degradation mechanism. Substrates that have to be degraded are targeted to the double-membrane vesicles called autophagosomes which ultimately fuse with lysosomes. Autophagosome is a hallmark feature of autophagy. Autophagy is mediated by evolutionarily conserved genes called autophagy-related genes (Atg) and their encoded proteins (ATGs). Various Atg and their functions have been studied in yeast at different stages of autophagy [17]. There are more than 30 ATGs that have been discovered and about 17-20 ATGs take part in forming conjugation complexes that are necessary for the initiation of autophagy and autophagosome formation [18].

Autophagy process includes six steps—initiation, nucleation, elongation, maturation, fusion, and degradation (Figure 1) that are dependent on various protein complexes like Unc-51-like kinase 1 (ULK1 complex), phosphoinositide 3-kinase (class III-PI3K) complex, ATG9 complex, ATG2-ATG18 complex, ATG8/LC3 complex, and ATG12 conjugation complex (Figure 2).

2.1. ULK1 Complex. Induction of autophagy is dependent on the kinase activity of ULK1 [19, 20]. It is found in the inactive form if nutrients are readily available as it is dephosphorylated by the mammalian target of rapamycin (mTOR). During stress, a decrease in intracellular energy or an increase in the AMP/ATP ratio under low energy level activates adenosine monophosphate kinase (AMPK) which acts as a metabolic sensor by regulating glucose and lipid metabolism. [19, 21, 22]. AMPK-mediated deactivation of mTOR and phosphorylation of ULK1 lead to the activation of the ULK1 complex which consists of ULK1/ATG1, ATG13, FIP200/ATG17 (FAK-family kinase-interacting protein), and ATG101. ATG13 gets dephosphorylated (highly phosphorylated under nutrient-rich conditions), which enables the binding of ULK1 and increases its kinase activity.

2.2. Class III-PI3K (Phosphoinositide 3-Kinase) Complex. The PI3K-III complex containing Beclin-1/ATG6, ATG14, VPS34, and VPS15 (vacuolar protein sorting 34 and 15) is activated by ULK1 complex which is also important in the formation of isolation membrane or phagophore. VPS34 and VPS15 are class III-PI3 kinases, and VPS34 acts as a catalytic subunit, whereas VPS15 acts as a regulatory subunit in this complex. This complex phosphorylates PIP2 (phosphatidylinositol bisphosphate) to PIP3 (phosphatidylinositol triphosphate) which is a prerequisite for the initiation and nucleation processes.

2.2.1. ATG9 and ATG2-ATG18 Complexes. Increase in the PIP3 concentration leads to the recruitment of other proteins such as DFCP1 (double FYVE domain-containing protein 1), WIPI/ATG18 (WD-repeat domain phosphoinositide-interacting protein 1), ATG2, and ATG9 at the phagophore formation site [23]. During phagophore formation, endoplasmic reticulum (in the form of omegasomes) works as a membrane source in the presence of DFCP1 and ATG2-WIPI/ATG18 complex [24–26], while ATG9 mediates the use of membrane vesicles from the endoplasmic reticulum, plasma membrane, and mitochondria. In plasma membrane, ATG16L and heavy chain clathrin interaction is required for the formation of autophagosome precursor [27, 28], whereas, in mitochondria, ATG5 and LC3 localization to the outer membrane of mitochondria is required, which serves as a cornerstone for phagophore formation [29].

2.3. ATG8/LC3 and ATG12 Conjugation Complexes. Another protein that is important for preautophagosomal elongation and maturation is MAP1LC3 (microtubule-associated proteins 1A/1B light chain 3) or LC3/Atg8. LC3 is found in cells in the inactive form, i.e., proLC3 which is converted to LC3-I by ATG4 (a cysteine protease). Along with LC3, ATG12 conjugation complex (ATG12-ATG5-ATG16) (E3-like protein) plays an important role in elongation and maturation of autophagosomal membrane as it helps in recruitment and conversion of LC3-I to LC3-II by adding phosphatidylethanolamine (PE) with the help of ATG7 (E1-like protein) and ATG3 (E2-like protein). This LC-II is recruited to the autophagosomal membrane through its lipid moiety and is not freely available in the cytoplasm like LC-I. When LC3-I is converted to LC3-II, autophagosome is elongated (marker to monitor autophagy) [30] and it becomes a vesicle that is called a mature autophagosome [31]. After completion, LC3 remains bound to the lumina. During nucleation and elongation, some adaptor proteins play important roles in cargo selection which is LC3-dependent. Ubiquitin-binding protein p62/sequestosome-1 (p62/SQSTM1), neighbor of BRCA1 (NBR1), nuclear dot protein 52KD (NDP52), and optineurin transport their cargos to nucleation site by their
LC3-interacting region (LIRs) or ATG8-interacting motifs (AIMs) which facilitate cargo selection as well as selective autophagy. Once the protein recruitment and formation of autophagosome are completed, the mature autophagosome with its contents fuses with lysosomes via sets of protein families: soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), including syntaxin-17 (STX17), synaptosomal-associated protein 29 (SNAP29), and vesicle-associated membrane protein 8 (VAMP8) [32]; Ras-related protein Rab-7 (Rab7); and HOPS (the homotypic fusion and protein sorting–tethering complex) [33]. After the fusion of the autophagosome with the lysosome, it becomes autolysosome. The autophagosome releases its content into the lysosome, and those substrates are degraded in the acidic environment of the lysosome by particular proteases (cathpsins B and L).

Alternative macroautophagy has been introduced which is independent of LC3-II, ATG5, and ATG7, but is critically dependent on ULK1 and Beclin1. It is debated whether it is a different form of autophagy [34]. At first, autophagy was believed to be a nonspecific degradative process. But now, many selective pathways have been demonstrated and are named according to the particular substrate that is degraded. For instance, for mitochondria, it is called mitophagy, for ferritin, it is called ferritinophagy, for ER, it is reticulophagy, for bacteria, it is xenophagy, etc. [35, 36].

3. Regulation of Autophagy

Nutritional status, energy level, growth factors, insulin ER stress, SOS (response when cells are exposed to stress causing DNA damage and cell cycle arrest), and other signals modulate the autophagy process by various target proteins. Of all target proteins, mTOR, also known as FRAP1, is a master regulator that negatively regulates autophagy [37, 38]. It consists of two complexes—mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2)—out of which, mTORC1 is sensitive to rapamycin. Rapamycin (sirolimus) is a mTOR inhibitor extracted from bacterium Streptomyces hygroscopicus.

In nutrient-rich conditions, mTORC1 hinders autophagosome formation and thus suppresses autophagy [39–42]. Upstream of mTORC1, growth factor receptors, and tyrosine kinase receptors get phosphorylated and activated which leads to the activation of PI3K either directly or indirectly via adapters such as GAB2 [growth factor receptor–bound 2–(GRB2–)associated-binding protein 2] and insulin receptor substrate 1 (IRS1) [43, 44]. Activated PI3K converts PI3P to PI3(3)P and recruits protein kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) and RAC-alpha serine/threonine-protein kinase 1 (AKT1). AKT1 gets activated by PDK1 which inhibits heterodimerization of tuberous sclerosis 1 (TSC1) and TSC2, resulting in inhibiting Ras homolog enriched in brain (Rheb) and hence activation of its GTPase activity. Phosphatase and tensin homolog (PTEN) is a tumor suppressor which dephosphorylates PI3P to PI3P and counterbalances the whole cascade (Figure 3) [45]. Loss of tumor suppressors like liver kinase B1 (LKB1), promyelocytic leukemia protein (PML), PTEN, and TSC1/2 or gain in function mutations can activate mTOR, thus inhibiting autophagy, whereas cellular stress and mTOR inhibitors like rapamycin, Torin 1, and Tamox downregulate or inhibit mTOR and induce autophagy [46, 47]. Another mTOR complex mTORC2 is involved in the activation and phosphorylation of AKT1 [8, 48, 49]. 6-TG (6-thioguanine) induces autophagy and requires activation of mTOR [50]. So, it is not universal that mTOR activity is inversely proportional to autophagy.

Hypoxia (low oxygen status which can be present in cells in poorly vascularized regions) activates autophagy through...
hypoxia-inducible factor- (HIF-) dependent and hypoxia-inducible factor- (HIF-) independent pathways [16, 51, 52]. The HIF-dependent pathway involves selective autophagy mediated by HIF1 and its target Bcl-2 nineteen-kilodalton-interacting protein 3 (BNIP3) [53, 54]. They are affected by the concentration of oxygen and some growth factors which lead to modulation in the regulation of erythropoiesis, angiogenesis, metabolism, pH regulation, cell migration, and tumor invasion [53] by increases in the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and nitric oxide synthase (NOS). BNIP3 activates Beclin1 by inhibiting Bcl-2 [52]. So, both HIF and BNIP3 are required for prosurvival hypoxia-induced autophagy in normal as well as in cancer cells [53–55]. Also, it has been seen that misfolded proteins can also regulate autophagy by binding itself to ER chaperone-binding immunoglobulin protein (BiP)/GRP78 and release three ER membrane-associated proteins: PKR-like eIF2a kinase (PERK), activating transcription factor-6 (ATF6), and inositol-requiring enzyme 1 (IRE1). PERK and ATF6 induce autophagy, whereas IRE1 inhibits [56].

Figure 2: Autophagy pathway in mammalian cells: initiation of autophagy is dependent on 6 protein complexes: ULK1 complex, class III-PI3K (phosphoinositide 3-kinase) complex, ATG9 complex, ATG2-ATG18 complex, ATG8/LC3 complex, and ATG12 conjugation complex.
3.1. Transcriptional Regulation of Autophagy. There are some transcriptional factors which act as upregulators or downregulators of autophagy. For example, transcription factor EB (TFEB), E2F transcription factor 1 (E2F1), activating transcription factor 4 (ATF4), Forkhead box O3 (FOXO3), nuclear factor erythroid-derived 2-like 2 (NRF2/NFE2L2), hypoxia-induced factor (HIF), p53, and peroxisome proliferator-activated receptor α (PPARα) are upregulators of autophagy, whereas zinc finger protein with KRAB and SCAN domains 3 (ZKSCAN3), heat shock factor (HSF), transcription factor 4 (TCF4), X-box binding protein 1 (XBP1), farnesoid X receptor (FXR), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) are suppressors of autophagy (Figure 4).

TFEB is the prime regulator of lysosomal biogenesis and gets activated by dephosphorylation during starvation which allows it to enter the nucleus to induce transcription of its targets such as Atg4, Atg16, LC3, p62, WIPI proteins, ULK1, and some cathepsins. [57–59] E2F1 is involved in stress-related mechanisms and is inhibited by NF-κB; it upregulates BNIP3, ULK1, LC3, and Atg5 and helps in the autophagosome initiation [60–63]. ATF4 is upregulated by itself and activated by severe hypoxia; it enters into the nucleus and upregulates autophagy machinery components ULK1, LC3, and Atg5 [62, 64, 65]. FOXO3 is inhibited by AKT (which is activated by PI3K). Activated FOXO (suppressed AKT and PI3K) enters the nucleus and activates Atg4, Atg2, Atg5, Atg12, Beclin1, LC3, and ULK1 [62, 66, 67]. NRF2 is regulated by amino acid content and nutrient signaling and upregulates p62. HIF is activated by mild hypoxia, whereas ATF4 is activated during severe hypoxic conditions [53, 54]. p53 comes into picture during DNA damage; it upregulates Atg4, Atg7, and ULK1 [62, 68, 69]. PPARα is activated during starvation, whereas, in the fed state, it is suppressed by FXR. PPARα induces Atg3, Atg5, Atg7, Beclin1, LC3, TFEB, and ULK1 [70–72].

ZKSCAN3 is a negative and major regulator of TFEB. In a fed state, it enters the nucleus and binds to autophagy machinery target genes such as ULK1, LC3, and WIPI proteins [62, 73]. HSF is opposite of NRF2 as it suppresses p62 [74]. TCF4 is regulated by β-catenin. TCF4 suppresses p62 when β-catenin binds to TCF4. But when LC3 binds to β-catenin, it leads to proteasomal degradation. So, β-catenin suppresses TCF4. XBP1 is activated by ER stress and enters the nucleus. It has a dual function by upregulating Beclin1 and suppressing FOXO3 which in turn suppresses Atg4, Atg5, Atg12, LC3, and ULK1 [62, 75]. FXR is a negative transcriptional repressor of PPARα and it inhibits genes of Atg3, Atg5, Atg7, Beclin1, L3, ULK1, and TFEB. NF-κB has dual effects; it enters the nucleus and upregulates Beclin1 and p62; on the other hand, it also inhibits E2F1, i.e., inhibits Atg5, LC3, and ULK1 [22, 62, 63, 76–78].

During starvation, calcium ions are released into the cytoplasm from lysosome and activate a phosphatase.
calcineurin which removes phosphate from TFEB (phosphorylated by mTOR in a fed state) and gets activated. During starvation, ZKSCAN and FXR are kicked out of the nucleus which allows TFEB and PPARα to enter into the nucleus, bind to its targets, and induce autophagy by induction of many autophagy proteins. During starvation, c-Jun also gets translocated into the nucleus which induces expression of ANXA2 (Annexin A2) which is important for increased secure autophagic trafficking [62, 79].

3.2. Regulation of Autophagy by p53.

p53 is the “guardian” of cell integrity. It is a tumor suppressor protein and is mutated in more than 50% of the cancers [80]. It is reported in almost every type of cancer ranging from 10% in hematopoietic malignancy [81], 20-40% or more in breast cancer, colorectal cancer [82], and other type of cancers [83], and 50-60% in esophageal carcinoma to approx. 100% in high-grade serous carcinoma of ovary [84]. Depending upon the stimuli and subcellular localization, it can function as a positive as well as a negative regulator of autophagy. Nuclear p53 acts as an activator of autophagy in a transcription-dependent or transcription-independent manner. AMPK gets activated by stress-activated p53 which upregulates autophagy by downregulating the mTOR pathway. p53 also induces activation of the autophagy pathway by upregulating damage-regulated autophagy modulators (DRAMs), Sestrin 1 and 2, and death-associated protein kinase 1 (DAPK1). DRAM (a lysosomal protein) stimulates autophagy at various stages of the autophagic process. DAPK-1 stimulates autophagy by inhibiting antiapoptotic microtubule-associated protein 1B (MAP1B) protein (an LC3 interactor). AMPK increases level of NAD⁺- and NAD⁺-dependent activity deacetylase Sirt1, which plays an important role in stimulation of autophagy by numerous ATG activations and deacetylations [85]. Cordani et al. reported that mutant p53 substantially counteracts the autophagic vesicle formation and fusion of these vesicles with lysosomes through the suppression of several important autophagy-related enzymes and proteins such as DRAM1, BECN1, and AMPK [86]. Nuclear p53 also releases Beclin1 via phosphorylation from the sequestration of Bcl-2/Bcl-xL/Mcl-1 [87]. It is also observed that deficiency of Beclin 1 is associated with deficiency in tumor suppressor p53, causing malignancies in BECN1-deficient mice [87–90]. Furthermore, p53 can also induce autophagy via transactivation of the p14ARF tumor suppressor (or p19ARF in mouse, or also known simply as ARF), which can stabilize p53 by inhibiting Mdm2 (E3 ubiquitin ligase) and subsequently inhibiting the proteasome-mediated degradation of p53 [91–94].

However, cytoplasmic p53 acts as an inhibitor of autophagy. It targets TP53-induced glycolysis and apoptosis regulator (TIGAR) gene that downregulates glycolysis and suppresses ROS, rather than via the mTOR pathway (Figure 5) [90, 95]. Tasdemir et al. and Sui et al. have reported that cytoplasmic p53 directly interacts with FIP200, thus regulating the crucial initiation step of autophagy [80, 90]. To induce autophagy, it is required to degrade cytoplasmic p53. p53⁻/⁻ cells do not show any autophagic response when transfected with p53 protein in the cytoplasm. It is due to the lack of nuclear p53 [80]. This dual role is not exclusive to p53; potent oncogene Ras also has been reported to portray this dual role [96–98].

Ataxia telangiectasia mutated (ATM) (a sensor of cellular or DNA damage during the cell cycle) and high mobility
group box 1 (HMGB1) (an immune modulator) also have been discovered as controllers of autophagy by regulating TSC2/mTORC1 signaling axis and interaction with Beclin1, respectively [99, 100].

4. Autophagy in Cancer

Cancer is a multifactorial disease characterized by uncontrolled cell division and can develop an obtrusive phenotype that is caused by genetic mutations, epigenetic alterations, and environmental factors that change the expression or function of the encoded products and behavioural factors [16]. GLOBOCAN (2018) estimated about 9.55 million deaths every year [101]. In India, about 0.7 to 0.81 million cancer-related deaths are estimated [102]. Cancer uses a variety of sources to meet the needs for unrestricted proliferation. It shifts towards anabolic metabolism and increases the Warburg effect (aerobic glycolysis) [103]. There are increasing evidence that autophagy regulates cancer cell’s life. Cancer is one of the major maladies that is linked to dysregulation of autophagy. Autophagy deficiency prompts oncogenic mutations, damaged organelles, and macromolecule accumulation hence inducing oxidative stress, chromatin instability, DNA damage, and tumor susceptibility [104–106].

Tumor cells have more reliance on autophagy for survival as compared to normal cells due to their rapid proliferative ability in the nutrient-deprived environment caused by them. Through the autophagy recycling process, cancer cells overcome metabolic stress during its rapid proliferation. Dysregulated autophagy has implications in both well-being and sickness, specifically in cancer. Autophagy plays a dichotomous job in cancer by restraining tumor commencement (as a tumor suppressor); on the other hand, it is supporting tumor progression [107]. A few key autophagic regulators and their related pathways which play important roles in the regulation of autophagy in cancer include the Beclin1 interactome, Ras-Raf-MAPK pathway, PIR-Akt-mTOR pathway, and TP53 signaling. Several signaling pathways and molecules may modulate the autophagy in cancer, and these agents may act as potential therapeutic targets in treatment of cancer [108].

4.1. Duality of Autophagy in Cancer. A key question is how autophagy plays a dual role in the regulation of cancer. It prevents the development of the cancerous cells; on the other hand, it behaves as a key mechanism for the survival of the cancer cells. It was initially thought that autophagy has a tumor-suppressive role in normal cells by constraining inflammation, tissue damage, and prevention from senescence induced by an oncogene, scavenging damaged organelles and macromolecules, preventing the accumulation of radicles which are toxic and cause instability of the genome, and restricting the metastasis of cancer cells [8]. Also, by limiting tumor necrosis and oncogene-induced increase in senescence during an early stage of metastasis of cancer can act as a metastasis suppressor.

However, autophagy has also been implicated in benefits of cancer cells by either of the two mechanisms: one is the mutation which leads to activation of oncogenes (e.g., PIK3CA Ras, RHEB, and AKT—autophagy inhibitors) and the second being mutations that result in inactivation of tumor suppressor genes (e.g., PTEN AMPK, LKB1, and TSC1/2—autophagy inducers) [9]. The initiation of neoplasia in various genetically engineered mouse models (GEMMs) has also been reported by deleting the autophagy genes for studying autophagy deficiency in cancer. Paradoxically, autophagy can supply nutrients to cancers and, in turn, enhances its survival. In the advanced stage of metastasis of
cancer, it promotes ECM disengagement of a metastatic cancer cell to a distinct site and also helps to enter the cell into dormancy if the cell fails to set up contact with ECM [109]. Additionally, as a response to therapy or to confer resistance to radiations and chemotherapy, autophagy gets frequently upregulated and protects cancer cells from apoptosis [8, 16, 110, 111].

4.1.1. Autophagy as a Tumor Suppressor. Autophagy is frequently downregulated in various types of tumors suggesting its tumor-suppressive role as discussed earlier [112–114]. Constitutive activation of PI3K-Akt-mTOR axis is known to suppress autophagy [115] and is a characteristic of cancer, by promoting the proliferation, growth, and survival of the tumor cells [116]. There are various proteins like Bcl-2-interacting Beclin1 (BECN1/ATG6), Atg4c [117], Bax-interacting factor-1 (Bif-1) [118], BH3-only proteins [7], DAP kinase [119], ultraviolet radiation resistance-associated gene (UVRAG) [120], and PTEN [121] involved in autophagy that shows its role in tumor suppression (Figure 6). There are also some tumor suppressors like LKB1 [8, 122], TSC [123], nuclear p53 [56], and AMPK [124] which regulate the mTORC pathway. Additionally, all ATGs show this tumor suppressor property. Several studies reported that the initiation of autophagy causes radiation sensitization in radioresistant and malignant glioma cells. Studies have also shown that certain chemotherapeutic drugs may destroy tumor cells through intrinsic pathway of apoptosis initiated by autophagy [125, 126].

(1) Beclin1 as a Tumor Suppressor. With the studies on Beclin1, it was first recognised that defective autophagy plays a role in cancer. Beclin1 is an ortholog of yeast Atg6/Vsp30 gene and is required for autophagy and vacuolar protein sorting processes [127]. It maps on the centromeric region of BRCA1 on 17q21 chromosome which is responsible for 75%, 50%, and 40% deletion in many cancers like ovarian, breast, and prostate cancers, respectively [128, 129]. Deletion in both BRCA1 and Beclin1 or only BRCA1 was found, but no proof of Beclin1 mutation or loss detected in any cancer which questions its tumor silencing activity in human cancer. But it is identified as a haploinsufficient tumor suppressor that is deleted monoallelically in cancer and decreases in autophagy [114]. It was the first direct link established between autophagy and cancer. Beclin1 was immuno-isolated in a screen for gene complements that shows its role in tumor suppression (Figure 6). Tissue specificity is seen in the Beclin1 tumor-suppressive function. In contradiction, colorectal and gastric cancer shows higher expression of Beclin1 about 95% and 83%, respectively, compared to the normal stomach and colon mucosa with very low and undetectable levels. The Beclin1 protein contains Bcl-2 homology-3 (BH3) domain which interacts with BH3 receptor domain of antiapoptotic proteins like Bcl-2 and Bcl-xL and inhibits Beclin1 autophagic activity as well as its tumor suppressor activity. BH3-only proteins and DAPK under nutrient deprivation induce autophagy by disrupting Beclin1 interaction to Bcl-2/Bcl-xL competitively [7, 130, 131].

(2) UVRAG as a Tumor Suppressor. Reactive oxygen species (ROS), dysfunctional mitochondria, and accumulation of toxic protein aggregates cause aneuploidy and genomic transformation in autophagy-deficient cells. Through UVRAG which was isolated in a screen for gene complementing UV sensitivity in xeroderma pigmentosum cells, autophagy can protect against the instability of genome and confer centrosome protection. UVRAG depletion leads to errors in chromosome segregation, malfunctioning of the spindle apparatus [8]. It is represented as a hub for regulating autophagy and cancer as it is a part of Beclin1 and Vps34 multifunctioning protein which behaves as type III PI3K and stimulates autophagy. Low levels of UVRAG cause impaired induction of autophagy. It does not only act early in the initiation of autophagy but also regulates later-on stages like maturation and fusion. Its phosphorylation by mTORC1 blocks the late stages of autophagy. It disrupts Beclin1, dimer stabilized by Bcl-2-like protein to induce autophagy in both in vivo and in vitro. Similar to Beclin1, it is deleted monoallelically. In colon and
gastric cancers, autophagy decreases and it is done by targeting adenine track of UVRAG gene (A10 in exon 8) for frameshift mutation [128, 129].

(3) Bif-1 as a Tumor Suppressor. Bif-1/endophilin B1, also known as SH3GLB1, is discovered originally as a Bax-binding protein. It is a third protein associated with the class III PI 3-kinase complex [132, 133]. It participates in vesicle formation and membrane dynamics with membranes of organelles of Golgi apparatus, mitochondria. [118]. During nutrient deprivation, Bif-1 along with LC3/ATG8, ATG5, and ATG9 autophagic effectors gets accumulated in the cytoplasmic puncta. It stimulates PI3K complex and regulates autophagy by interacting with Beclin1 through UVRAG, although it does not appear to be a constitutive subunit of the complex. Bif-1 is established as a suppressor, as bif1−/− mice, and suppresses autophagosome formation and enhances the lymphomas and tumor development [7].

(4) An ATG Protein as a Tumor Suppressor. It was reported that Beclin1−/− mice die early in embryogenesis and aging; mice with Beclin1+/− are tumor-prone [134, 135], whereas mice with Atg5−/− and Atg7−/− are born normally, but die soon due to low nutritional level and suckling defects in neonates [136, 137]. As compared to Atg5−/− iBMK cells, Atg5−/− iBMK cells are more tumorigenic in nude mouse allografts [106]. Also, in Atg7-deficient liver, neither cell proliferation nor tumorigenesis was observed [136]. Functions of ATG5 and Beclin1 act as “guardians” of the cellular genome. During ischaemic stress parallel with tumorigenesis, their loss displays gene amplification, aneuploidy, and DNA damage. Also, as compared to ATG5 and ATG7, Beclin1-dependent and Beclin1-independent properties play an important role during embryonic development and tumor suppression. Further autophagy defects playing a role in tumorigenesis are confirmed by Atg4C−/− mice (autophagin-3 cysteine protease involved in the processing of LC3), show decreased autophagy which is starvation induced, and also develop fibrosarcoma by chemical carcinogen induction. Cysteine-specific residues in active sites of protein cause ROS-mediated oxidation due to which Atg4C appears as ROS sensor in autophagy [117, 138]. From the discussion, it is found that autophagy acts as a tumor suppressor and its reduced function is a hallmark of cancer.

4.2. Autophagy: Role in Resistance to Therapy. Autophagy is activated in response to a variety of cancer therapies and may induce cancer cell survival or chemoresistance as an adaptive cellular response [100, 139, 140, 148]. Accumulation of autophagosome has been observed in cancer cells after they were exposed to various chemotherapeutics like temozolomide DNA alkylating agent [149], tamoxifen an estrogen receptor antagonist [150], resveratrol [151], vitamin D3, and anthocyanins [152]. Along with these chemotherapeutics, hypoxia, hyperthermia, and radiotherapy activate and upregulate autophagy, thus enabling a dormancy state in the cancerous cells which can lead to tumor reoccurrence and progression [118, 130]. Evidence showed enhanced efficiency of anticancer drugs on tumor cells with inhibited autophagy. Chloroquine inhibits autophagy and also enhances the efficacy of p53 or DNA alkylating agent to induce tumor regression or cell death in c-Myc-induced lymphomas in mice [131]. Through pharmacological means or by knocking down Atgs like Atg5, Atg6, and Atg7 is a major therapeutic means for sensitizing cells to anticancer therapies. Studies have reported that Akt inhibitors like triciribine and
perifosine can initiate protective autophagy among tumor cells. Perifosine can also increase the rapamycin cytotoxicity in multiple myeloma by suppressing the PI3K/Akt/mTOR pathway [108]. Furthermore, studies have shown that metformin can suppress progression of tumor by activating AMPK in melanoma and cervical cancer and thus by causing autophagy [153, 154]. Cancer cells can be sensitized to radio- and chemotherapies by siRNA-mediated depletion of ATG proteins, e.g., miRNA-22 is shown to influence chemotherapy-resistant colon cancer cells by inhibiting autophagy and promoting apoptosis [111, 155]. Overexpression of miR-22 in colon cancer cells increased sensitivity to 5-FU which is one of the main chemotherapeutic agents used in the treatment of colorectal cancer [156]. miR-409-3p inhibits autophagy by targeting Beclin-1 resulting in enhanced sensitivity to oxaliplatin. miRNA-210 induces autophagy and reduces radiosensitivity in colon cancer [58]. In a study, miR137 chemosensitize pancreatic cancer cells and inhibit autophagy by targeting Atg5 [157]. It has also been seen that long noncoding RNAs (lncRNAs) and CAIF (cardiac autophagy inhibitory factor) modulate autophagy and prevent defective autophagy-mediated loss of cardiac myocytes. It could be a potential therapeutic tool for the treatment of myocardial infarction and heart failure [158]. Other noncoding RNAs like circular RNA (Hsa-circ0023404) have a role in cervical cancer progression, metastasis, and chemoresistance through autophagy by sponging miR5047 [159]. Thus, it is clear that miRNA and any other noncoding RNAs regulate autophagy under various stress conditions. Various strategies are available to deliver the knockout materials (miRNAs or siRNA) to the target cancer cells such as nanoparticles, lipid vectors, nonlipid vectors, and multistage vector (MSV) delivery system. Lipid vectors such as liposomes and stable nucleic acid lipid particles (SNALPs) and nonlipid vectors such as chitosan, poly(amidoamine) dendrimers, and polyethyleneimines are used [160]. Cyclodextrin nanoparticles can be used as an effective tumor targeting, as the surface is decorated with transferrin protein targeting ligand since the transferrin receptors are overexpressed on the surface of cancer cells [161]. Radiosensitization of malignant glioma cells can also be caused by using autophagy inhibitors like 3-methyladenine and bafilomycin A1 [162].

4.2.1. Pharmacological Modulation of Autophagy to Countercact Cancer. Activators of autophagy are considered effective in neurodegenerative diseases, whereas inhibitors of autophagic flux such as chloroquine are considered effective in cancer therapy. It is a fact that autophagy in normal cells is beneficial and the use of its inhibitors as cancer therapy is a major obstacle [8]. So, a drug that targets the autophagic pathway in cancer cells without affecting normal cells could be an ideal drug. This novel paradigm in cancer therapy has been validated in several preclinical studies and is now under investigation in I/II phase of clinical trials involving autophagy inhibition. Antimalarial drug hydroxychloroquine, which blocks lysosomal degradation of the autophagy products by affecting lysosomal pH, in combination with anticancerous drugs involved in standard chemotherapy to achieve better outcomes. Table 1 shows a few of the clinical trials based on the antimalarial drugs in combination with different anticancer drugs used for the inhibition of autophagy. They support that targeting autophagy provides therapeutic benefits in models of chemotherapy resistance and shows very promising results in combinatorial cancer treatment.

Apart from inhibition of autophagy as a tumor-suppressive mechanism in the early stages of tumor formation, there may be a benefit in identifying activators of autophagy as anticancer agents as well. Significant attempts are being devoted to the development of autophagy modulator agents with enhanced pharmacological specificity. Activators such as IFNy, melatonin, and trehalose and inhibitors such as LY294002 are in clinical trials, whereas activators such as A-769662, BECN1-derived peptide, and BRD5631 and inhibitors such as compound C (also known as dorsomorphin), Mdivi-1, Lys05, SAR405, VPS34-1N1, SBI-0206965, MRT67307, NSC185058, and MRT68921 are in preclinical development stage [163]. There is little evidence that induction of autophagic cell deaths can also be used as a therapeutic strategy for removing cells with high apoptotic threshold or compromised apoptosis cancerous cells lacking BAK, BAX, and caspases. For instance, thalidizine in various cancer cell lines eliminates apoptotic resistance via autophagic cell death [164]; four dauricine derivatives induce autophagy-dependent cell death in HeLa cells [165]. Some natural products in in vivo studies like polyphyllin (PPI) extracted from rhizome Paris polyphylla activate AMPK directly and suppress the growth of non-small-cell lung cancer (NSLC) [166]. Ethoxyxanguinarine, an alkaloid extracted from Macleaya cordata, induces autophagy cell death in breast cancer cells [167]. Various rapamycin derivatives such as CCI-799, RAD001, and AP23573 can also be used as effective therapeutic agents against cancer [168]. In combination with chemotherapeutic agents, autophagic cell death is also found in in vitro cancer cells. In MCF-7, the silencing of Bcl-2 by siRNA leads to autophagic cell death. Further siRNA in combination with a low dose of doxorubicin enhances autophagy which inhibits tumor growth and leads to autophagic cell death [169]. Various potential drugs and their nanoformulations such as Doxil (liposomal formulation of doxorubicin) which is a first approved nanodrug used in breast cancer therapy and Abraxane (albumin-bound paclitaxel formulation) can be used in combinational strategies to improve therapeutic effect and reduce the toxicity and side effects [160]. But after all this, future studies are needed to prove that manipulation of autophagy can be useful in clinics.

4.3. Autophagy and Immune System. Autophagy is an important catabolic pathway which plays several roles in different kinds of cells [170]. Autophagy is also necessary for complete macrophage differentiation of mice and human monocytes driven by granulocyte-macrophage colony-stimulating factor (GM-CSF) or colony-stimulating factor-1 (CSF-1) [171]. The initiation of autophagy is crucial for differentiation and survival of monocytes. The signal of differentiation discharges Bcl-2 interacting coiled coil protein-1 (Beclin-1) from Bcl-2 by c-Jun N-terminal kinase (JNK) activation and preventing cleavage of ATG5 which are important for induction of
autophagy [172]. Prevention of autophagy initiation hinders production of cytokines and differentiation. Hence, autophagy is vital in the conversion from apoptosis of monocyte to differentiation (Figure 7) [172]. In innate immune system, autophagy also modifies cell-specific functions like phagocytosis and antigen presentation. Autophagy can also play a role in microbial defense like antimicrobial peptide production and antigen presentation as pathogens/microbes can be engulfed directly in autophagolysosomes [170].

5. Conclusion and Future Perspective

Autophagy is a cell’s recycling machinery, degrades cytosolic substrates in lysosomes, and provides by-products (biomolecules) which are used in anabolic processes and help cells survive in stress conditions. It is under tight regulation of mTOR, various transcriptional factors, p53 localization, etc. Thus, autophagy plays an important role not only in normal cells but also in cancer cell progression. It acts as a double-edged sword; on the one hand, it promotes tumor survival by providing energy and maintains homeostasis, whereas on the other hand, its defects elevate oxidative stress, damage, and mutations which are linked to tumor initiation and progression. It acts as a tumor suppressor during initial stages of cancer but becomes a tumor progressor in advanced stages. It is also responsible for providing resistance against various cancer therapies. Blocking autophagy is an approach to treat established, aggressive cancer, providing a promising hope for clinical applications. Inhibition of autophagy by pharmacological means or by ATG knockdown can promote cancer autophagy [172].

| Compound (autophagy inhibitor) | Indication | Phase | Trial ref # at ClinicalTrials.gov |
|-------------------------------|------------|-------|----------------------------------|
| Chloroquine (CQ)              | Small-cell lung cancer | I     | NCT00969306                     |
| Chloroquine + tamoxifen       | Breast cancer | II    | NCT02333890                     |
| Velcade and cyclophosphamide with CQ | Multiple myeloma | II    | NCT01438177                     |
| Cisplatin and etoposide + CQ  | Stage 4 small-cell lung cancer | I     | NCT00969306                     |
|                                | Non-small-cell lung cancer | II    | NCT00933803                     |
|                                | Colorectal cancer | II    | NCT01006369                     |
| Hydroxychloroquine (combination treatment) | Advanced cancer | I     | NCT01266057                     |
| Hydroxychloroquine + ixabepilone | Rectal cancer, colon cancer, metastasis, adenocarcinoma | II    | NCT01206530                     |
| Hydroxychloroquine + docetaxel | Melanoma (skin) | I     | NCT00962845                     |
| Hydroxychloroquine + vorinostat | Renal cell carcinoma | I     | NCT01144169                     |
| Hydroxychloroquine + combination treatment | Unspecified adult solid tumor | I | NCT00908831                     |
| Hydroxychloroquine + bortezomib | Breast cancer | II    | NCT00765765                     |
| Hydroxychloroquine + gemcitabine | Prostate cancer | II    | NCT00786682                     |
| Gemcitabine and Abraxane with or without HCQ | Advanced solid tumor | I | NCT01023737                     |
| Hydroxychloroquine + bortezomib | Lung cancer | II    | NCT00728845                     |
| Hydroxychloroquine + gemcitabine | Multiple myeloma and plasma cell neoplasm | II  | NCT00568880                     |
| Hydroxychloroquine + gemcitabine | Pancreatic cancer | II    | NCT01128296                     |
| Hydroxychloroquine + bortezomib | Prostate cancer | II    | NCT01978184                     |
| Hydroxychloroquine + gemcitabine | Prostate cancer | II    | NCT01506973                     |

Table 1: Antimalarial drug combinations are used for cancer treatment in various preclinical studies [173–175].
cell death and could be therapeutically advantageous but only without affecting normal cells. Other than autophagy regression, its contradictory role, i.e., tumor suppression at the early stages of cancer development, should also be considered. More effort has to be put on the development of effective cancer-specific delivery systems and drugs to make tumor more sensitized to therapies. In addition, a detailed deciphering of the crucial role of noncoding RNAs in autophagy has profound clinical implications. Therefore, along with combinational therapies with the conventional one, more effort should be put on the miRNA-based therapies for therapy-resistant cancers.

The role of autophagy in the development and maintenance of cancer is thoroughly studied, but still there are many aspects of this that need to be addressed. The cancer cells maintain higher basal level autophagy which supports their survival even under various hypoxic conditions and its regulation mechanism is still not fully understood. Also, enlightenment on the mechanism of cargo selection for this heightened basal level autophagy in cancer cells has not been elucidated. Many autophagy-related genes are studied which play an important part in protection and development of therapeutic resistance in various cancer cells, but their regulation and molecular mechanisms are yet to be deciphered fully. The scope of understanding tumor microenvironment is getting attention since tumors can develop and proliferate in various stressful hypoxic and hypoglycemic conditions. This characteristic of cancer is mainly attributed to increased autophagy in cancerous cells. Thus, understanding the interaction between tumor microenvironment and autophagy is of utmost importance which involves various in vivo as well as organotypic culture studies. These aspects of autophagy can be highly advantageous in developing various therapeutic regimens which can impede tumor development and progression as well as countering therapeutic resistance. Last but not the least, a lot of effort is still needed to understand the types of various cancers that would be controlled using autophagy inhibition which will depend on the development of newer and better biomarkers of autophagy in cancer.

Conflicts of Interest

The authors declare that they have no conflict of interest associated with this manuscript.

Authors’ Contributions

KD, AKV, PSB, and SR conceived the idea. SR, AKV, and PSB performed the literature search and wrote the manuscript. PSB, AKV, and SR made vital contribution to write-up and diagrams. AKV, DB, YG, KKP, SR, SAA, MAA, AHR, and AA provided inputs for the strategy and final edition of the article. All authors read and approved the final manuscript. Amit Kumar Verma, Prahalad Singh Bharti, and Sahar Rafat contributed equally to this work.

Acknowledgments

We thank Jamia Millia Islamia for providing Internet facility and access to journals. We acknowledge DST-SERB, Department of Science and Technology, Government of India, India, for funding the project of autophagy and cancer (grant number SB/EMEQ-094/2014).

References

[1] Y. C. Kim and K. L. Guan, “mTOR: a pharmacologic target for autophagy regulation,” The Journal of Clinical Investigation, vol. 125, no. 1, pp. 25–32, 2015.
[2] M. M. Mihaylova and R. J. Shaw, “The AMPK signaling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, no. 9, pp. 1016–1023, 2011.
[3] T. P. Neufeld, “TOR-dependent control of autophagy: biting the hand that feeds,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 157–168, 2010.
[4] P. Boya, F. Reggiori, and P. Codogno, “Emerging regulation and functions of autophagy,” Nature Cell Biology, vol. 15, no. 7, pp. 713–720, 2013.
[5] H. Sandoval, P. Thiagarajan, S. K. Dasgupta et al., “Essential role for Nix in autophage maturation of erythroid cells,” Nature, vol. 454, no. 7201, pp. 232–235, 2008.
[6] M. Chen, H. Sandoval, and J. Wang, “Selective mitochondrial autophagy during erythroid maturation,” Autophagy, vol. 4, no. 7, pp. 926–928, 2014.
[7] M. C. Maiuri, E. Tasdemir, A. Criollo et al., “Control of autophagy by oncogenes and tumor suppressor genes,” Cell Death and Differentiation, vol. 16, no. 1, pp. 87–93, 2009.
[8] A. Brech, T. Ahliquist, R. A. Lothe, and H. Stenmark, “Autophagy in tumour suppression and promotion,” Molecular Oncology, vol. 3, no. 4, pp. 366–375, 2009.
[9] A. M. K. Choi, S. W. Ryter, and B. Levine, “Autophagy in human health and disease,” The New England Journal of Medicine, vol. 368, no. 7, pp. 651–662, 2013.
[10] L. G. Paavola, “The corpus luteum of the guinea pig: III. Cytochemical studies on the Golgi complex and GERL during normal postpartum regression of luteal cells, emphasizing the origin of lysosomes and autophagic vacuoles,” The Journal of Cell Biology, vol. 79, no. 1, pp. 59–73, 1978.
[11] W. J. Dyche, “A comparative study of the differentiation and involution of the Mullerian duct and Wolffian duct in the male and female fetal mouse,” Journal of Morphology, vol. 162, no. 2, pp. 175–209, 1979.
[12] H. J. Helminen and J. L. E. Ericsson, “Ultrastructural studies on prostatic involution in the rat. Mechanism of autophagy in epithelial cells, with special reference to the rough-surfaced endoplasmic reticulum,” Journal of Ultrastructure Research, vol. 36, no. 5–6, pp. 708–724, 1971.
[13] J. Debnath, E. H. Baehrecke, and G. Kroemer, “Does autophagy contribute to cell death?,” Autophagy, vol. 1, no. 2, pp. 66–74, 2005.
[14] J. M. Levy and A. Thorburn, “Targeting autophagy during cancer therapy to improve clinical outcomes,” Pharmacology & Therapeutics, vol. 131, no. 1, pp. 130–141, 2011.
[15] R. Amaravadi, A. C. Kimmelman, and E. White, “Recent insights into the function of autophagy in cancer,” Genes & Development, vol. 30, no. 17, pp. 1913–1930, 2016.
Autophagy: process and function, "Genes & Development", vol. 21, no. 22, pp. 2861–2873, 2007.

[8] Y. Feng, D. He, Z. Yao, and D. J. Klionsky, "The machinery of macroautophagy," Cell Research, vol. 24, no. 1, pp. 24–41, 2014.

[9] C. H. Jung, C. B. Jun, S. H. Ro et al., "ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery," Molecular Biology of the Cell, vol. 20, no. 7, pp. 1992–2003, 2009.

[10] Y.-Y. Chang and T. P. Neufeld, "An Atg1/Atg13 complex with multiple roles in TOR-mediated autophagy regulation," Molecular Biology of the Cell, vol. 20, no. 7, pp. 2004–2014, 2009.

[11] I. G. Ganley, D. H. Lam, J. Wang, X. Ding, S. Chen, and X. Jiang, "ULK1+ATG13+FIP200 Complexes mediate mTOR Signaling and Is Essential for Autophagy," The Journal of Biological Chemistry, vol. 284, no. 18, pp. 12297–12305, 2009.

[12] N. Hosokawa, T. Hara, T. Kaizuka et al., "Nutrient-dependent mTORC1 association with the ULK1–Atg13–FIP200 complex required for autophagy," Molecular Biology of the Cell, vol. 20, no. 7, pp. 1981–1991, 2009.

[13] M. Cully, H. You, A. J. Levine, and T. W. Mak, "Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis," Nature Reviews Cancer, vol. 6, no. 3, pp. 184–192, 2006.

[14] T. Pawson, "Specificity in signal transduction: from phosphotyrosine–SH2 domain interactions to complex cellular systems," Cell, vol. 116, no. 2, pp. 191–203, 2004.

[15] D. D. Sarbassov, S. M. Ali, and D. M. Sabatini, "Growing roles for the mTOR pathway," Current Opinion in Cell Biology, vol. 17, no. 6, pp. 596–603, 2005.

[16] S. Pattingre, L. Espert, M. Biard-Piechaczyk, and P. Codogno, "Regulation of macroautophagy by mTOR and Beclin 1 complexes," Biochimie, vol. 90, no. 2, pp. 313–323, 2008.

[17] H. Takeuchi, Y. Kondo, K. Fujiwara et al., "Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors," Cancer Research, vol. 65, no. 8, pp. 3336–3346, 2005.

[18] E. Kim, P. Goraksha-Hicks, L. Li, T. P. Neufeld, and K.-L. Guan, "Regulation of TORC1 by Rag GTPases in nutrient response," Nature Cell Biology, vol. 10, no. 8, pp. 935–945, 2008.

[19] Y. Sancak, T. R. Peterson, Y. D. Shaul et al., "The Rag GTpases bind raptor and mediate amino acid signaling to mTORC1," Science, vol. 320, no. 5882, pp. 1496–1501, 2008.
[50] S. Jacob, M. Aguado, D. Fallik, and F. Praz, “The role of the DNA mismatch repair system in the cytotoxicity of the topo-isomerase inhibitors camptothecin and etoposide to human colorectal cancer cells,” Cancer Research, vol. 61, no. 17, pp. 6555–6562, 2008.

[51] M. P. DeYoung, P. Horak, A. Sofer, D. Sgroi, and L. W. Ellis, “Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling,” Genes & Development, vol. 22, no. 2, pp. 239–251, 2008.

[52] G. L. Semenza, “HIF-1: upstream and downstream of cancer metabolism,” Current Opinion in Genetics & Development, vol. 20, no. 1, pp. 51–56, 2010.

[53] G. Bellot, R. Garcia-Medina, P. Gounon et al., “Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains,” Molecular and Cellular Biology, vol. 29, no. 10, pp. 2570–2581, 2009.

[54] H. Zhang, M. Bosch-Marce, L. A. Shimoda et al., “Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia,” The Journal of Biological Chemistry, vol. 283, no. 16, pp. 10892–10903, 2008.

[55] S. Wilkinson, J. O’Prey, M. Fricker, and K. M. Ryan, “Hypoxia-selective macroautophagy and cell survival signaled by autocrine PDGF activity,” Genes & Development, vol. 23, no. 11, pp. 1283–1288, 2009.

[56] A. Criollo, L. Senovilla, H. Authier et al., “The IKK complex contributes to the induction of autophagy,” The EMBO Journal, vol. 29, no. 3, pp. 619–631, 2009.

[57] J. A. Martina, Y. Chen, M. Gucek, and R. Puertollano, “MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB,” Autophagy, vol. 8, no. 6, pp. 903–914, 2014.

[58] A. Fesler, H. Liu, N. Wu, F. Liu, P. Ling, and J. Ju, “Autophagy regulated by miRNAs in colorectal cancer progression and resistance,” Cancer Translational Medicine, vol. 3, no. 3, pp. 96–100, 2017.

[59] J. D. Rahinowitz and E. White, “Autophagy and metabolism,” Science, vol. 330, no. 6009, pp. 1344–1348, 2010.

[60] S. Polager, M. Ofr, and D. Ginsberg, “E2F1 regulates autophagy and the transcription of autophagy genes,” Oncogene, vol. 27, no. 35, pp. 4860–4864, 2008.

[61] A. Garcia-Garcia, H. Rodriguez-Rocha, M. T. Tseng et al., “E2F-1 lacking the transcriptional activity domain induces autophagy,” Cancer Biology & Therapy, vol. 13, no. 11, pp. 1091–1101, 2012.

[62] J. Fullgrabe, G. Ghislat, D.-H. Cho, and D. C. Rubinsztein, “Transcriptional regulation of mammalian autophagy at a glance,” Journal of Cell Science, vol. 129, no. 16, pp. 3059–3066, 2016.

[63] R. K. Bruck, “Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9082–9087, 2000.

[64] T. Rzymski, M. Milani, L. Pike et al., “Regulation of autophagy by ATF4 in response to severe hypoxia,” Oncogene, vol. 29, no. 31, pp. 4424–4435, 2010.

[65] L. R. G. Pike, D. C. Singleton, F. Buffa et al., “Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival,” The Biochemical Journal, vol. 449, no. 2, pp. 389–400, 2013.

[66] C. J. Bowman, D. E. Ayer, and B. D. Dynlacht, “Foxk proteins repress the initiation of starvation-induced atrophy and autophagy programs,” Nature Cell Biology, vol. 16, no. 12, pp. 1202–1214, 2014.

[67] Y.-A. Kang, R. Sanalkumar, H. O’Geen et al., “Autophagy driven by a master regulator of hematopoiesis,” Molecular and Cellular Biology, vol. 32, no. 1, pp. 226–239, 2011.

[68] J. M. Rosenbluth, D. J. Mays, M. F. Pino, L. J. Tang, and J. A. Pietenpol, “A gene signature-based approach identifies mTOR as a regulator of p73,” Molecular and Cellular Biology, vol. 28, no. 19, pp. 5951–5964, 2008.

[69] D. Kenzelmann Broz, S. Spano Mello, K. T. Bieging et al., “Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses,” Genes & Development, vol. 27, no. 9, pp. 1016–1031, 2013.

[70] S. Seok, T. Fu, S. E. Choi et al., “Transcriptional regulation of autophagy by an FXR–CREB axis,” Nature, vol. 516, no. 7529, pp. 108–111, 2014.

[71] J. M. Lee, M. Wagner, R. Xiao et al., “Nutrient-sensing nuclear receptors coordinate autophagy,” Nature, vol. 516, no. 7529, pp. 112–115, 2014.

[72] M. Jiao, F. Ren, L. Zhou et al., “Peroxisome proliferator-activated receptor activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway,” Cell Death & Disease, vol. 5, no. 8, article e1397, 2014.

[73] S. Chauhan, J. G. Goodwin, S. Chauhan et al., “ZKSCAN3 is a master transcriptional repressor of autophagy,” Molecular Cell, vol. 50, no. 1, pp. 16–28, 2013.

[74] T. Luo, J. Fu, A. Xu et al., “PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression,” Autophagy, vol. 12, no. 8, pp. 1355–1371, 2016.

[75] A. Margariti, H. Li, T. Chen et al., “XBP1 mRNA Splicing Triggers an Autophagic Response in Endothelial Cells through BECLIN-1Transcriptional Activation,” The Journal of Biological Chemistry, vol. 288, no. 2, pp. 859–872, 2013.

[76] J. Ling, Y. Kang, R. Zhao et al., “KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma,” Cancer Cell, vol. 21, no. 1, pp. 105–120, 2012.

[77] T. Copetti, C. Bertoli, E. Dalla, F. Demarchi, and C. Schneider, “p65/RelA modulates BECN1 transcription and autophagy,” Molecular and Cellular Biology, vol. 29, no. 10, pp. 2594–2608, 2009.

[78] D. Tang, R. Kang, T. Vanden Berghe, P. Vandenabeele, and G. Kroemer, “The molecular machinery of regulated cell death,” Cell Research, vol. 28, 2013.

[79] K. Moreau, G. Ghislat, W. Hochfeld et al., “Transcriptional regulation of Annexin A2 promotes starvation-induced autophagy,” Nature Communications, vol. 6, no. 1, article 8045, 2015.

[80] E. Tasdemir, M. C. Maiuri, L. Galluzzi et al., “Regulation of autophagy by cytoplasmic p53,” Nature Cell Biology, vol. 10, no. 6, pp. 676–687, 2008.

[81] S. Peller and V. Rotter, “TP53 in hematological cancer: low incidence of mutations with significant clinical relevance,” Human Mutation, vol. 21, no. 3, pp. 277–284, 2003.
counteract autophagic mechanism sensitizing cancer cells to induced modulator of autophagy, is critical for apoptosis, vol. 7, no. 6, pp. 565–571, 2014.

M. Mrakovic and L. Fröhlich, “p53-mediated molecular control of autophagy in tumor cells,” Biomolecules, vol. 8, no. 2, p. 14, 2018.

T. Denisenko, A. Pivnyuk, and B. Zhivotovsky, “p53-autophagy-metastasis link,” Cancer, vol. 10, no. 5, p. 148, 2018.

X. Sui, L. Jin, X. Huang, S. Geng, C. He, and X. Hu, “p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment,” Autophagy, vol. 7, no. 6, pp. 565–571, 2014.

D. Crighton, S. Wilkinson, J. O’Prey et al., “DRAM, a p53-induced modulator of autophagy, is critical for apoptosis,” Cell, vol. 126, no. 1, pp. 121–134, 2006.

Z. Feng, H. Zhang, A. J. Levine, and S. Jin, “The coordinate regulation of the p53 and mTOR pathways in cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 23, pp. 8204–8209, 2005.

B. Levine and J. Abrams, “p53: the Janus of autophagy?, Nature Cell Biology, vol. 10, no. 6, pp. 637–639, 2008.

M. C. Maiuri, S. A. Malik, E. Morselli et al., “Stimulation of autophagy by the p53 target gene Sestrin2,” Cell Cycle, vol. 8, no. 10, pp. 1571–1576, 2014.

E. White, “Autophagy and p53,” Cold Spring Harbor Perspectives in Medicine, vol. 6, no. 4, article a026120, 2016.

S. Furuta, E. Hidaka, A. Ogata, S. Yokota, and T. Kamata, “Ras is involved in the negative control of autophagy through the class I PI3-kinase,” Oncogene, vol. 23, no. 22, pp. 3898–3904, 2004.

M. Elgendy, C. Sheridan, G. Brumatti, and S. J. Martin, “ Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival,” Molecular Cell, vol. 42, no. 1, pp. 23–35, 2011.

L. Y. Mah and K. M. Ryan, “Autophagy and cancer,” Cold Spring Harbor Perspectives in Biology, vol. 4, no. 1, article a008821, 2012.

D. Tang, R. Kang, K. M. Livesey et al., “Endogenous HMGB1 regulates autophagy,” The Journal of Cell Biology, vol. 190, no. 5, pp. 881–892, 2010.
in U251-MG and U87-MG human malignant glioma cells,” Journal of Neuro-Oncology, vol. 68, no. 2, pp. 101–111, 2004.

[119] S. Bialik and A. Kimchi, “Lethal weapons: DAP-kinase, autophagy and cell death,” Current Opinion in Cell Biology, vol. 22, no. 2, pp. 199–205, 2010.

[120] C. Liang, P. Feng, B. Ku et al., “Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG,” Nature Cell Biology, vol. 8, no. 7, pp. 688–698, 2006.

[121] T. E. Rusten, K. Lindmo, G. Juhász et al., “Programmed Autophagy in the Drosophila Fat Body Is Induced by Ecdysone through Regulation of the PI3K Pathway,” Developmental Cell, vol. 7, no. 2, pp. 179–192, 2004.

[122] D. M. Eccles, G. Cranston, C. M. Steel, Y. Nakamura, and R. C. Leonard, “Allele losses on chromosome 17 in human epithelial ovarian carcinoma,” Oncogene, vol. 5, no. 10, pp. 1599–1601, 1990.

[123] X. Zhou, T. Ikenoue, C. Liang, P. Feng, B. Ku et al., “Autophagy mitigates metabolic stress and genome damage in mammalian tumorigenesis,” Genes & Development, vol. 21, no. 13, pp. 1621–1635, 2007.

[124] S. L. Lomonaco, S. Finniss, C. Xiang et al., “The induction of autophagy by γ-radiation contributes to the radioreistance of glioma stem cells,” International Journal of Cancer, vol. 125, no. 3, pp. 717–722, 2009.

[125] W. Zhuang, Z. Qin, and Z. Liang, “The role of autophagy in sensitizing malignant glioma cells to radiation therapy,” Acta Biochimica et Biophysica Sinica, vol. 41, no. 5, pp. 341–351, 2009.

[126] Y.-M. Kim, C. H. Jung, M. Seo et al., “The role of autophagy in tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene,” The Journal of Clinical Investigation, vol. 122, no. 12, pp. 425–434, 2005.

[127] S. Kametaka, T. Okano, M. Ohsumi, and Y. Ohsumi, “Apg14p and Apg6/Vps30p Form a Protein Complex Essential for Autophagy in the Yeast, Saccharomyces cerevisiae,” The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22284–22291, 1998.

[128] K. A. Battista, M. Resnati, C. Facchi et al., “Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation,” PLoS One, vol. 13, no. 8, article e0201621, 2018.

[129] J.-H. Ryu, J. Y. Yoo, M. J. Kim et al., “Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 2, pp. 549–561, 2013.

[130] T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1809–1820, 2003.

[131] Z. Yue, S. Jin, C. Yang, A. J. Levine, and N. Heintz, “Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15077–15082, 2011.

[132] M. Komatsu, S. Waguri, M. Koike et al., “Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice,” The Journal of Cell Biology, vol. 169, no. 3, pp. 425–434, 2005.

[133] A. Kuma, M. Hatano, M. Matsu et al., “The role of autophagy during the early neonatal starvation period,” Nature, vol. 432, no. 7020, pp. 1032–1036, 2004.

[134] R. Scherz-Shouval, E. Shvets, E. Fass, H. Shorer, L. Gil, and Z. Elazar, “Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4,” The EMBO Journal, vol. 26, no. 7, pp. 1749–1760, 2007.

[135] E. White and R. S. DiPaola, “The double-edged sword of autophagy modulation in cancer,” Clinical Cancer Research, vol. 15, no. 17, pp. 5308–5316, 2009.

[136] X. Qu, J. Yu, G. Bhagat et al., “Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1809–1820, 2003.

[137] R. Mathew, C. M. Karp, B. Beaudoin et al., “Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability,” Human Pathology, vol. 39, no. 7, pp. 1041–1050, 2008.

[138] R. Scherz-Shouval, E. Shvets, E. Fass, H. Shorer, L. Gil, and Z. Elazar, “Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4,” The EMBO Journal, vol. 26, no. 7, pp. 1749–1760, 2007.

[139] E. White and R. S. DiPaola, “The double-edged sword of autophagy modulation in cancer,” Clinical Cancer Research, vol. 15, no. 17, pp. 5308–5316, 2009.

[140] R. Mathew, C. M. Karp, B. Beaudoin et al., “Frameshift mutation of UVRAG, an autophagy-related gene, in gastric carcinomas with microsatellite instability,” Human Pathology, vol. 39, no. 7, pp. 1041–1050, 2008.

[141] J. P. Witz, “Tumor-Microenvironment Interactions: Dangerous Liaisons,” Advances in Cancer Research, vol. 100, pp. 203–229, 2008.

[142] R. Lock and J. Debnath, “Extracellular matrix regulation of autophagy,” Current Opinion in Cell Biology, vol. 20, no. 5, pp. 583–588, 2008.

[143] H. Wei, S. Wei, B. Gan, X. Peng, W. Zou, and J.-L. Guan, “Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis,” Genes & Development, vol. 25, no. 14, pp. 1510–1527, 2011.

[144] E. White, “The role for autophagy in cancer,” The Journal of Clinical Investigation, vol. 125, no. 1, pp. 42–46, 2015.

[145] M. Komatsu, S. Waguri, M. Koike et al., “Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice,” Cell, vol. 131, no. 6, pp. 1149–1163, 2007.

[146] S. Kongara and V. Karantza, “The interplay between autophagy and ROS in tumorigenesis,” Frontiers in Oncology, vol. 2, 2012.

[147] R. A. Battista, M. Resnati, C. Facchi et al., “Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation,” PLoS One, vol. 13, no. 8, article e0201621, 2018.

[148] J.-H. Ryu, J. Y. Yoo, M. J. Kim et al., “Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 2, pp. 549–561, 2013.

[149] T. Kanzawa, I. M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo, “Role of autophagy in tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1809–1820, 2003.

[150] W. Bursch, A. Ellinger, H. Kienzl et al., “Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the
role of autophagy,” Carcinogenesis, vol. 17, no. 8, pp. 1595–1607, 1996.

[151] A. W. Opipari Jr., L. Tan, A. E. Boitano, D. R. Sorenson, A. Aurora, and J. R. Liu, “Resveratrol-induced autophagy in ovarian cancer cells,” Cancer Research, vol. 64, no. 2, pp. 696–703, 2004.

[152] J. Wang, H. Lian, Y. Zhao, M. A. Kauss, and S. Spindel, “Vitamin D3 induces autophagy of human myeloid leukemia cells,” The Journal of Biological Chemistry, vol. 283, no. 37, pp. 25596–25605, 2008.

[153] T. Tomic, T. Botton, M. Cerezo et al., “Metformin inhibits melanoma development through autophagy and apoptosis mechanisms,” Cell Death & Disease, vol. 2, no. 9, p. e199, 2011.

[154] X. Xiao, Q. He, C. Lu et al., “Metformin impairs the growth of liver kinase B1-intact cervical cancer cells,” Gynecologic Oncology, vol. 127, no. 1, pp. 249–255, 2012.

[155] M. Tiwari, V. K. Bajpai, A. A. Sahasarabudhe et al., “Inhibition of N-(4-hydroxyphenyl)retinamide-induced autophagy at a lower dose enhances cell death in malignant glioma cells,” Carcinogenesis, vol. 29, no. 3, pp. 600–609, 2007.

[156] H. Zhang, J. Tang, C. Li et al., “miR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells,” Cancer Letters, vol. 356, no. 2, pp. 781–790, 2015.

[157] Z. C. Wang, F. Z. Huang, H. B. Xu, J. C. Sun, and C. F. Wang, “MicroRNA-137 inhibits autophagy and chemoresists pancreatic cancer cells by targeting ATG5,” The International Journal of Biochemistry & Cell Biology, vol. 111, pp. 63–71, 2019.

[158] C.-Y. Liu, Y. H. Zhang, R. B. Li et al., “lncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardian transcription,” Nature Communications, vol. 9, no. 1, p. 29, 2018.

[159] J. Guo, M. Chen, G. Ai, W. Mao, H. Li, and J. Zhou, “Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047,” Biomedicine & Pharmacotherapy, vol. 115, p. 108957, 2019.

[160] H. Shen, V. Mittal, M. Ferrari, and J. Chang, “Delivery of gene silencing agents for breast cancer therapy,” Breast Cancer Research, vol. 15, no. 3, p. 205, 2013.

[161] N. C. Bellocq, S. H. Pun, G. S. Jensen, and M. E. Davis, “Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery,” Bioconjugate Chemistry, vol. 14, no. 6, pp. 1122–1132, 2003.

[162] H. Ito, S. Daido, T. Kanazawa, S. Kondo, and Y. Kondo, “Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells,” International Journal of Oncology, vol. 26, no. 5, pp. 1401–1410, 2005.

[163] L. Galluzzi, J. M. Bravo-San Pedro, B. Levine, D. R. Green, and G. Kroemer, “Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles,” Nature Reviews. Drug Discovery, vol. 16, no. 7, pp. 487–511, 2017.

[164] B. Y. K. Law, F. Gordillo-Martínez, Y. Q. Qu et al., “Thalidomide, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death,” Oncotarget, vol. 8, no. 18, pp. 30077–30091, 2017.

[165] X. Zhou, Y. Q. Qu, Z. Zheng et al., “Novel dauricine derivatives suppress cancer via autophagy-dependent cell death,” Bioorganic Chemistry, vol. 83, pp. 450–460, 2019.

[166] Y. Wu, Y. Si, Y. Xiang et al., “Polyphyllin I activates AMPK to suppress the growth of non-small-cell lung cancer via induction of autophagy,” Archives of Biochemistry and Biophysics, vol. 687, article 108285, 2020.

[167] Y. Si, J. Wang, X. Liu et al., “Ethoxysanguinarine, a novel direct activator of AMP-activated protein kinase, induces autophagy and exhibits therapeutic potential in breast cancer cells,” Frontiers in Pharmacology, vol. 10, p. 1503, 2020.

[168] Y. P. Yang, L. F. Hu, H. F. Zheng et al., “Application and interpretation of current autophagy inhibitors and activators,” Acta Pharmacologica Sinica, vol. 34, no. 5, pp. 625–635, 2013.

[169] J. M. Zarzynska, “The importance of autophagy regulation in breast cancer development and treatment,” BioMed Research International, vol. 2014, Article ID 710345, 9 pages, 2014.

[170] N. Germic, Z. Frangez, S. Yousefi, and H.-U. Simon, “Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation,” Cell Death and Differentiation, vol. 26, no. 4, pp. 715–727, 2019.

[171] A. Jacquel, S. Obba, L. Boyer et al., “Autophagy is required for CSF-1–induced macrophage differentiation and acquisition of phagocytic functions,” Blood, vol. 119, no. 19, pp. 4527–4531, 2012.

[172] Y. Zhang, M. J. Morgan, K. Chen, S. Choksi, and Z. Liu, “Induction of autophagy is essential for monocyte-macrophage differentiation,” Blood, vol. 119, no. 12, pp. 2895–2905, 2012.

[173] C. I. Chude and R. K. Amaravadi, “Targeting autophagy in cancer: update on clinical trials and novel inhibitors,” International Journal of Molecular Sciences, vol. 18, no. 6, p. 1279, 2017.

[174] M. Marinković, M. Šprung, M. Buljubašić, and I. Novak, “Autophagy modulation in cancer: current knowledge on action and therapy,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 8023821, 18 pages, 2018.

[175] J. M. M. Levy, C. G. Towers, and A. Thorburn, “Targeting autophagy in cancer,” Nature Reviews. Cancer, vol. 17, no. 9, pp. 528–542, 2017.